Dosing Flexibility Study in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and
4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and
16. At Wk 18 patients will be grouped as responders or non-responders based on results of the
ACR20 at Week 16.